> 90 % as determined by SDS-PAGE
< 1.0 EU per μg of the protein as determined by the LAL method
1. Measured by its binding ability in a functional ELISA. Immobilized recombinant human IL-6 at 8 μg/mL (100μl/well) can bind recombinant human IL6R with a linear range of 1.25-20.0 ng/ml.
2. Measured by its ability to enhance the IL6 activity on M1 mouse myeloid leukemia cells. The ED50 for this effect is typically 20-80 ng/ml.
A DNA sequence encoding the extracellular domain of human IL6R (NP_000556.1) corresponding to amino acid (Met 1-Pro 365) was expressed with a C-terminal polyhistidine tag.
Predicted N Terminal
The soluble form of recombinant human IL6R consists of 357 amino acids and has a predicted molecular mass of 40 kDa. In SDS-PAGE under reducing conditions, it migrates with an apparent molecular mass of 60-65 kDa due to glycosylation.
Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us
for any concerns or special requirements.Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -70℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
CD126 Protein, Human;gp80 Protein, Human;IL-6R Protein, Human;IL-6R-1 Protein, Human;IL-6RA Protein, Human;IL6Q Protein, Human;IL6RA Protein, Human;IL6RQ Protein, Human
Interleukin 6 receptor (IL-6R) also known as CD126 (Cluster of Differentiation 126) is a type I cytokine receptor. The low concentration of a soluble form of IL-6 receptor (sIL-6R) acts as an agonist of IL-6 activity. In the IL-6R/CD126/IL6R system, both a membrane-bound IL-6R and a sIL-6R protein are able to mediate IL-6 signals into the cells through the interaction of gp130. The resulting IL-6/sIL-6R protein complex is also capable of binding to gp130 and inducing intracellular signalling. Through this so-called 'trans-signalling' mechanism, IL-6 is able to stimulate cells that lack an endogenous mIL-6R. High levels of IL-6 and sIL-6R have been reported in several chronic inflammatory and autoimmune diseases as well as in cancer.
Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
Barill S, et al. (2000) The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw. 11(4): 546-51. Kang KW, et al. (2007) Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cells. Free Radic Biol Med. 42(2): 215-27.